ABBVIE INC. (ABBV) Financials
Key financial figures for ABBVIE INC. (Q3 2026).
AbbVie's Q3 2026 adjusted diluted EPS of $3.82 topped its own $3.73-$3.77 guide, and full-year 2026 adjusted EPS guidance was raised to $13.95-$13.99 from $13.76-$13.96. Net revenues were $17.404 billion, up 10.3% reported (10.5% operational). Adjusted diluted EPS was $3.82 against $1.86 a year earlier; GAAP diluted EPS was $2.37 against $0.10. Both include a $0.11 per share hit from acquired IPR&D and milestones expense ($216 million pre-tax), versus $2.680 billion of that expense in Q3 2025. Against expectations: adjusted EPS of $3.82 is $0.09 above the $3.73 estimate on our earnings calendar (FMP-sourced) and above the $3.73-$3.77 Q3 range AbbVie itself gave in its October 5, 2026 8-K (that range already included the $0.11 IPR&D charge). On the outlook: Full-year 2026 adjusted diluted EPS guidance raised from $13.76 - $13.96 to $13.95 - $13.99, which includes an unfavorable $0.69 per share from acquired IPR&D and milestones expense incurred year-to-date through the third quarter; the range excludes any such expense beyond Q3. The prior $13.76 - $13.96 range was set in AbbVie's October 5, 2026 8-K and already included the $0.11 Q3 charge. Dividend raised 5.2% to $1.82 per quarter from the February 2027 payment. Figures are for Q3 2026, as AbbVie Inc. reported them.
- Revenue
- $17.4B
- Net Income
- $4.2B
- EPS
- $2.38
- Total Assets
- $147.7B
- Operating Cash Flow
- $7.6B
Recent quarters
| Period | Revenue | Net Income | EPS | Operating Margin | Free Cash Flow |
|---|---|---|---|---|---|
| Q3 FY2026 | $17.4B | $4.2B | $2.37 | 37.25% | $7.3B |
| Q2 FY2026 | $17.0B | $3.6B | $2.03 | 37.86% | $3.1B |
| Q1 FY2026 | $15.0B | $699M | $0.39 | 31.56% | $3.6B |
| Q4 FY2025 | $16.6B | $1.8B | $1.02 | 34.96% | $4.9B |
| Q3 FY2025 | $15.8B | $186M | $0.10 | 12.07% | $6.6B |
Recent fiscal years
| Period | Revenue | Net Income | EPS | Operating Margin | Free Cash Flow |
|---|---|---|---|---|---|
| FY2025 | $61.2B | $4.2B | $2.36 | 32.85% | $17.8B |
| FY2024 | $56.3B | $4.3B | $2.39 | 16.22% | $17.8B |
| FY2023 | $54.3B | $4.9B | $2.72 | 23.49% | $22.1B |
Frequently asked questions
What was AbbVie Inc.'s revenue last quarter?
AbbVie Inc. reported revenue of $17.40 billion for Q3 FY2026, up 10.3% from the same period a year earlier.
Is AbbVie Inc. profitable?
Yes. AbbVie Inc. reported net income of $4.22 billion for Q3 FY2026, a net margin of 24.26% on revenue.
How has AbbVie Inc.'s margin trended?
Operating margin was 37.25% in Q3 FY2026, compared with 12.07% in the same period a year earlier. The quarter by quarter series is on the SentiSense financials page.
How much free cash flow did AbbVie Inc. generate?
AbbVie Inc. generated free cash flow of $7.31 billion in Q3 FY2026, after capital expenditure.
Full income statement, balance sheet and cash flow for ABBVIE INC. on SentiSense, with up to forty quarters and twenty fiscal years of history.